App-Quantinova.ai

Systemic sclerosis physiotherapy in the digital age

Sebri Addous - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Scleroderma

N/A

Optical coherence tomography of the skin detects scleroderma changes in clinically unaffected skin: an opportunity for early detection of systemic sclerosis

Giuseppina Abignano - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Scleroderma

N/A

Cross-validation and complementary value of optical coherence tomography and high frequency ultrasound for the assessment of skin disease in systemic sclerosis

Duygu Temiz Karadag - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Scleroderma

N/A

Biosamples from at risk SSc patients show classic pathological signs of scleroderma: opportunity for a diagnosis of pre-clinical SSc

Rebecca L Ross - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Can non-invasive techniques be used to image calcinosis?

Tonia L Moore - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Raynaud syndrome

N/A

A pilot study of oxygenation and perfusion in systemic sclerosis-related digital ulcers

Joanne B Manning - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Scleroderma

N/A

How well does deep learning differentiate between optoacoustic and optical nailfold capillaroscopy images from patients with systemic sclerosis versus those from healthy controls?

Suhanyaa Nitkunanantharajah - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Pulmonary hypertension in patients with systemic sclerosis: an audit of screening practices, incidence and cost over 10 years

Luke Spray - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

N/A

Modelling macrophage-fibroblast interaction in scleroderma to evaluate new treatments

Linda Lei - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Scleroderma

N/A

Predictors of renal survival in a cohort of patients with lupus nephritis with more than 30 years of follow-up

Filipa Farinha - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Lupus nephritis

N/A

Anti-domain I positivity in SLE at diagnosis is predictive of atherosclerotic plaque development

Thomas C. R McDonnell - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Progression of subclinical cardiovascular disease in SLE: a five year follow up study

Jyoti Bakshi - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

USEFUL I: musculoskeletal ultrasound to identify patients with lupus arthritis with better response to therapy

Khaled Mahmoud - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Osteoarthritis

Prednisolone

MASTERPLANS: prediction of response to rituximab in SLE using a validated two-score system for interferon

Ade Alase - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Mycophenolate mofetil

A retrospective analysis of aortitis cases from radiology reports in a London teaching hospital: implications for screening and management

Katherine Townsend - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Aortic wall inflammation

N/A

Art in dialogue: art and voice in an ANCA-associated vasculitis workshop

Shanali Perera - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anti-neutrophil cytoplasmic antibody-associated vasculitis

N/A

Glucocorticoid exposure and link to serious adverse events in patients with ANCA-associated vasculitis

Philip Spearpoint - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Anti-neutrophil cytoplasmic antibody-associated vasculitis

Glucocorticoid

External validation of the Southend GCA Probability Score (GCAPS) as a screening tool for referrals with possible GCA

Vanessa Quick - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Prednisolone

Detection of anti-neutrophil cytoplasmic antibodies: a single-centre evaluation of the value of indirect immunofluorescence versus antigen-specific immunoassays

Natasha Cleaton - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

SJ8903

Prevalence and mortality of ANCA-associated vasculitis in England

Fiona A Pearce - British Society for Rheumatology (BSR) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Eosinophilic granulomatosis with polyangiitis

N/A

Filters

45280 Abstracts